The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2024 | Morbidities and malignancy in patients with thalassemia
In this video, Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, outlines the differences in morbidities observed in patients with transfusion-dependent and non-transfusion-dependent thalassemia (TDT and NTDT, respectively). Prof. Taher also briefly discusses malignancy in aging patients with thalassemia. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Novo Nordisk, Bristol-Myers Squibb (Celgene), Vifor, Pharmacosmos, Agios; Research funding: Bristol-Myers Squibb (Celgene), Vifor, Pharmacosmos, Agios.
